{
  "id": "58c1b2f702b8c6095300001e",
  "type": "list",
  "question": "List 3 indications for Bupropion",
  "ideal_answer": "Bupropion is used to treat Obesity, for smoking cessation and for depression",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/17227286",
    "http://www.ncbi.nlm.nih.gov/pubmed/15479310",
    "http://www.ncbi.nlm.nih.gov/pubmed/16831112",
    "http://www.ncbi.nlm.nih.gov/pubmed/9554323",
    "http://www.ncbi.nlm.nih.gov/pubmed/16546007",
    "http://www.ncbi.nlm.nih.gov/pubmed/12043548",
    "http://www.ncbi.nlm.nih.gov/pubmed/21274361",
    "http://www.ncbi.nlm.nih.gov/pubmed/25661549",
    "http://www.ncbi.nlm.nih.gov/pubmed/18619194",
    "http://www.ncbi.nlm.nih.gov/pubmed/15155135",
    "http://www.ncbi.nlm.nih.gov/pubmed/10804045",
    "http://www.ncbi.nlm.nih.gov/pubmed/25223901",
    "http://www.ncbi.nlm.nih.gov/pubmed/27038550",
    "http://www.ncbi.nlm.nih.gov/pubmed/21142259",
    "http://www.ncbi.nlm.nih.gov/pubmed/23859696",
    "http://www.ncbi.nlm.nih.gov/pubmed/26137782",
    "http://www.ncbi.nlm.nih.gov/pubmed/16027765",
    "http://www.ncbi.nlm.nih.gov/pubmed/25895022",
    "http://www.ncbi.nlm.nih.gov/pubmed/18264876",
    "http://www.ncbi.nlm.nih.gov/pubmed/18219560"
  ],
  "snippets": [
    {
      "text": " For genotype, genes associated with nicotinic acetylcholine receptors (nAChRs) and related proteins have been found to predict response to first-line medications (e.g. nicotine replacement therapy [NRT], bupropion, or varenicline) or quitting over time without a controlled treatment trial. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25895022",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The approval of drug combinations, such as phentermine/topiramate and bupropion/naltrexone are also noteworthy, the components of which have been previously approved, but not necessarily for obesity as main indication.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137782",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two drugs, phentermine plus topiramate and lorcaserin, have recently been approved by the US Food and Drug Administration for the indication of obesity; a third, bupropion plus naltrexone, is under consideration for approval. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25223901",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bupropion SR is preferred to subjects with depression or smokers who have failed with the previous two agents, due to the many contra-indications and side effects of bupropion SR. With one of the 3 agents combined with follow-up visits with counselling, one can expect a 1-year quit rate around 20-25%.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18619194",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In vitro intrinsic clearances were likewise different for bupropion enantiomers.CONCLUSIONS: Stereoselective bupropion hydroxylation may have implications for the therapeutic efficacy of bupropion as an antidepressant or smoking cessation therapy, and for the use of bupropion as an in vivo phenotypic probe for CYP2B6 activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18219560",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Hydroxylation of the antidepressant and smoking deterrent drug bupropion is a clinically important bioactivation and elimination pathway.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18219560",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although not U.S. Food and Drug Administration approved for these indications, bupropion has also been used as an adjunctive treatment to reverse antidepressant-induced sexual dysfunction and to augment anti-depressant efficacy in partial responders and non-responders to other agents.Bupropion has played and will continue to play an important role as a treatment for major depressive disorder in adults, as well as for other related disorders",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16027765",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinically, bupropion is used as a treatment for two indications, as an antidepressant, the indication for which it was developed, and as a tobacco use cessation agent",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17227286",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sustained release bupropion (amfebutamone) is a non-nicotine agent that is indicated as an aid to smoking cessation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10804045",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bupropion was introduced for smoking cessation following a pivotal trial showing that it gave improved efficacy over the nicotine patch and also suggesting combination treatment was beneficial. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23859696",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Compared with a placebo control, bupropion approximately doubles smoking quit rates. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16831112",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Over the past decade, bupropion has become a major pharmacotherapy for smoking cessation in the Western world. Unlike other smoking cessation pharmacotherapies, bupropion is a non-nicotine treatment",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16831112",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bupropion has been tested in over 40 controlled clinical trials and has been associated with higher rates of treatment discontinuation due to adverse events than NRTs. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21142259",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bupropion SR is a useful oral and non-nicotine form of pharmacotherapy for smoking cessation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12043548",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "everal new drugs for the treatment of obesity are either licensed in some parts of the world, submitted for registration, or completing phase III trials. These include combinations (at low dose) of existing drugs, e.g., bupropion + naltrexone (Contrave),",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25661549",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016642",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016540",
    "http://www.biosemantics.org/jochem#4095874",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056687",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061485",
    "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4276121",
    "http://www.biosemantics.org/jochem#4276121"
  ],
  "exact_answer": "weight loss in obesity, smoking cessation, depression"
}